Louis Lacombe

Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer., Guillemette C, Fradet Y, Têtu B, Turcotte V, Rouleau M, Caron P, Lacombe L, Laverdière I, Lévesque É, Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, 10.1158/1078-0432.ccr-13-1100

The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy., Guillemette C, Lévesque É, Lacombe L, Fradet Y, Caron P, Audet-Walsh É, Flageole C, Laverdière I, Endocrine-related cancer, 2014, 10.1530/erc-14-0423

Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients., Rätsch G, Cancer Genome Atlas Research Network, Sander C, Kohlbacher O, Stegle O, Sachsenberg T, Stark SG, Hüser M, Toussaint NC, Lehmann KV, Kahles A, Cancer cell, 2018, 10.1016/j.ccell.2018.07.001

Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer., Lacombe L, Fradet Y, Harel F, Larue H, Hovington H, Patry G, International journal of cancer, 2008, 10.1002/ijc.23240

Prostatic intraepithelial neoplasia in TURP specimens and subsequent prostate cancer., Fradet Y, Lacombe L, Bairati I, Têtu B, Meyer F, The Canadian journal of urology, 2006

A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers., Akbani R, Williams C, Sumazin P, Li X, Schultz A, Rao A, Ravikumar V, Shen H, Fan H, Liu Y, Liu W, Lenoir W, Hegde AM, Kanchi RS, Korkut A, Berger AC, Cancer cell, 2018, 10.1016/j.ccell.2018.03.014

Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer., Toren P, Lacombe L, Guillemette C, Fradet Y, Dagenais F, Hovington H, D Wallis CJ, Joncas FH, Kourbanhoussen K, Asian journal of andrology, 2022, 10.4103/aja.aja_58_21

Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors., Fradet Y, Meyer F, Têtu B, Larue H, Moore L, Vezina MC, Lacombe L, Pfister C, Human pathology, 1999, 10.1016/s0046-8177(99)90067-9

Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy, Vincent Fradet, Karine Robitaille, Yves Fradet, Rabi Tiguert, Thierry Dujardin, Michele Lodde, Paul Toren, Louis Lacombe, Narcisse Singbo, Jean-François Pelletier, Samuel Fradet, Clinical Nutrition ESPEN, 2022, 10.1016/j.clnesp.2021.12.011

Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer., Kassouf W, Drachenberg D, Bell D, Saad F, Lattouf JB, Lacombe L, Cagiannos I, Rendon R, Fairey A, Estey E, Izawa J, Fradet Y, Chin JL, Aprikian AG, Yafi FA, World journal of urology, 2013, 10.1007/s00345-013-1207-z

A Simple Variable Number of Tandem Repeat-Based Genotyping Strategy for the Detection of Handling Errors and Validation of Sample Identity in Biobanks., Chevalier S, Carmel M, Lacombe L, Saad F, Aprikian AG, McKercher G, Pellerin C, Biopreservation and biobanking, 2016, 10.1089/bio.2015.0113

A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily., Akbani R, Ravikumar V, Ling S, Roszik J, Datto M, Kwong LN, Robertson G, Berger AC, Lorenzi PL, Li X, Schultz A, Gough NR, Rao S, Kanchi RS, Zaidi S, Korkut A, Cell systems, 2018, 10.1016/j.cels.2018.08.010

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma., Linehan WM, Godwin AK, Gibbs RA, Choueiri TK, Bottaro DP, Beroukhim R, Akbani R, Gibb EA, Bowlby R, Reznik E, Lang M, Smith CC, Fan H, De Cubas AA, Ricketts CJ, Cell reports, 2018, 10.1016/j.celrep.2018.06.032

Abstraits AUQ 2013, Haddad R, Aharony S, Sun M, Karakiewicz P, Trinh Q, Perrotte P, Tian Z, Gandaglia G, Abdo A, Hanna N, Kluth L, Shariat S, Roghmann F, Becker A, Trudeau V, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2013

Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review., Fradet V, Lacombe L, Fradet Y, Robitaille K, Lamarche B, Ben-Zvi T, Allaire J, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4471

Quality indicators in the management of bladder cancer: A modified Delphi study., Kassouf W, Izawa J, Gotto G, Fradet Y, Fleshner N, Fairey A, Eapen L, Drachenberg D, Chung P, Chin J, Brimo F, Booth C, Blais N, Black P, Aprikian A, Khare SR, Urologic oncology, 2017, 10.1016/j.urolonc.2016.12.003

PROGRAMME SCIENTIFIQUE * SCIENTIFIC PROGRAM Association des urologues du QUébec * Qué Urological Association Congrès annuel * Annual Meeting 9 au 11 novembre 2007 * November 9-11, 2007 Hôtel Hyatt Regency Montréal Centre-Ville, Montréal PQ., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2007

Substratification of high-risk localised prostate cancer treated by radical prostatectomy., Fradet Y, Lacombe L, Harel F, Lodde M, World journal of urology, 2008, 10.1007/s00345-008-0252-5

Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression., Guillemette C, Droit A, Leclercq M, Villeneuve L, Caron P, Turcotte V, Brisson H, Rouleau M, Melo-Garcia L, Allain ÉP, Hovington H, Labriet A, Lévesque E, British journal of cancer, 2020, 10.1038/s41416-020-0749-2

Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration., Pouliot F, Beauregard JM, Fradet Y, Makao-Nguile M, Fradet V, Lacombe L, Tiguert R, Dujardin T, Duchesnay N, Blouin AC, Buteau FA, Bergeron M, Lavallée E, European urology focus, 2018, 10.1016/j.euf.2018.03.008

The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients., Fradet Y, Tetu B, Tiguert R, Dujardin T, Lacombe L, Fradet V, Mauermann J, European urology, 2012, 10.1016/j.eururo.2012.08.002

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer., Zoledronic Acid Prostate Cancer Study Group, Zheng M, Goas JA, Vinholes JJ, Chin JL, Lacombe L, Venner P, Tchekmedyian S, Murray R, Gleason DM, Saad F, Journal of the National Cancer Institute, 2004, 10.1093/jnci/djh141

Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration., Lacombe L, Saad F, Bell D, Lattouf JB, So A, Chin J, Tanguay S, Black P, Kapoor A, Izawa J, Fairey A, Jacobsen N, Rendon R, Kassouf W, Mauermann J, Fradet V, Urologic oncology, 2014, 10.1016/j.urolonc.2014.04.006

Routine nasogastric tubes are not required following cystectomy with urinary diversion: a comparative analysis of 430 patients., Fradet Y, Lacombe L, Tiguert R, Harel F, Inman BA, The Journal of urology, 2003, 10.1097/01.ju.0000092500.68655.48

Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas., Greene CS, Schultz N, Ciriello G, Mina M, Cherniack AD, Sander C, Luna A, Chatila WK, Armenia J, La K, Sanchez-Vega F, Way GP, Cell reports, 2018, 10.1016/j.celrep.2018.03.046

Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer., Foley R, Fink C, Dekaban GA, Mukherjee SD, Hotte S, Landry C, Peretz Y, Favre D, Yassine-Diab B, Eady R, Salter RD, Finn OJ, Bergeron A, Major P, Scheid E, Cancer immunology research, 2016, 10.1158/2326-6066.cir-15-0189

¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy., Pouliot F, Buteau FA, Beauregard JM, Fradet V, Toren P, Tiguert R, Lodde M, Lacombe L, Fradet Y, Dujardin T, Lavallée É, Dubois G, Goulet CR, Otis-Chapados S, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7107

Blood management and radical retropubic prostatectomy: Quebec experience., Fradet Y, Lacombe L, The Canadian journal of urology, 1999

Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada., Black P, Jacobson NE, Fairey A, Fradet Y, Lacombe L, Saad F, Lattouf JB, Matsumoto E, Kapoor A, Chin J, Izawa J, Bell D, Rendon R, Kassouf W, Metcalfe M, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012, 10.5489/cuaj.12146

Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text., Kassouf W, Rendon RA, McPherson V, Lacombe L, Izawa JI, Hanna N, French C, Fairey A, Brimo F, Breau RH, Aprikian AG, Siemens DR, Kulkarni GS, Kool R, Bhindi B, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7367

Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: results from a Canadian multicenter collaboration., Kassouf W, Kapoor A, Lattouf JB, Lacombe L, Cagiannos I, Rendon R, Jacobsen N, Estey E, Fairey A, Fradet Y, Chin JL, Izawa JI, Aprikian AG, Bachir BG, Urologic oncology, 2014, 10.1016/j.urolonc.2013.10.016

A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies., Bristow RG, Hoogland AM, Verhoef EI, van Leenders GJLH, Kweldam CF, Gopalan A, Mahamud O, Bhandari V, Lalonde E, Murgic J, Pintilie M, Lo W, Chua MLK, European urology, 2017, 10.1016/j.eururo.2017.04.034

2017 NSAUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4896

Analysis of p21WAF1/CIP1 in primary bladder tumors., Cordon-Cardo C, Reuter VE, Fair WR, Gerald WL, Silver D, Orlow I, Lacombe L, Oncology research, 1996

Dose-dependent antihypertensive efficacy and tolerability of perindopril in a large, observational, 12-week, general practice-based study., CONFIDENCE Investigators, Yang K, Anand S, Tsoukas G, American journal of cardiovascular drugs : drugs, devices, and other interventions, 2011, 10.2165/11587000-000000000-00000

2015 CUA Abstracts, Kulkarni S, Power N, Punjani N, Leong H, Pautler S, Sener A, Chambers A, Brugarolas J, Tram A, Pardhan S, Sonke E, Tailly T, Mazzola C, Willie C, Power N, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015

CUA guidelines on the management of non-muscle invasive bladder cancer., Black P, Izawa JI, Siemens DR, Aprikian AG, Rendon R, Lacombe L, So A, Fairey A, Zlotta A, Breau RH, Kulkarni GS, Traboulsi SL, Kassouf W, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015, 10.5489/cuaj.3320

Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors., Cordon-Cardo C, Reuter VE, Dalbagni G, Lacombe L, Lianes P, Orlow I, Cancer research, 1994

Pathogenic Germline Variants in 10,389 Adult Cancers., Ding L, Cherniack AD, Krassowski M, Scott AD, Oak N, Wyczalkowski MA, Reynolds S, Paczkowska M, Oh C, Wang J, Ritter DI, Wu Y, Mashl RJ, Huang KL, Cell, 2018, 10.1016/j.cell.2018.03.039

Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes., Fradet Y, Meyer F, Tetu B, Veilleux C, Lacombe L, Moore L, Larue H, Pfister C, International journal of cancer, 2000, 10.1002/(sici)1097-0215(20000120)89:1<100::aid-ijc16>3.0.co;2-q

Best practices for enhancing surgical research: a perspective from the Canadian Association of Chairs of Surgical Research, Keijzer R, Ellsmere J, Wallace C, Seely AJ, Sabbagh R, Perrault LP, Lacombe L, Fehlings MG, Cayabyab FS, Brindle M, Barralet J, Auger FA, Anderson CC, Sener A, Canadian journal of surgery. Journal canadien de chirurgie, 2019, 10.1503/cjs.012619

Cigarette smoking and chromosome 9 alterations in bladder cancer., Scher H, Reuter VE, Lacombe L, Lianes P, Dalbagni G, Connolly-Jenks C, Cao PQ, Millon TV, Lu ML, Orlow I, Cordon-Cardo C, Shu XM, Zhang ZF, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 1997

Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy., Guillemette C, Klotz L, Lévesque É, Lacombe L, Caron P, Ding K, Vélot L, Morin F, Toren P, Neveu B, Rouleau M, Pouliot F, The Journal of urology, 2020, 10.1097/ju.0000000000000699

Canadian Urological Association, 63rd Annual Meeting, Edmonton, AB, June 22-25, 2008., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2008

Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level., Fradet Y, Laverdière J, Lacombe L, Rigaud J, Tiguert R, The Journal of urology, 2003, 10.1097/01.ju.0000075351.51838.b3

Cystatin C for early detection of acute kidney injury after laparoscopic partial nephrectomy., Caumartin Y, Lacombe L, Dujardin T, Bergeron A, Nadeau G, Alesawi A, Urology annals, 2014, 10.4103/0974-7796.140988

Canadian guidelines for the management of small renal masses (SRM)., Finelli A, Moore R, Drachtenberg D, Pautler S, Kapoor A, Cagiannos I, Leveridge M, Kassouf W, Tanguay S, Karakiewicz PI, Lacombe L, Rendon R, Jewett MA, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015, 10.5489/cuaj.2969

Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome., Reuter VE, Herr HW, Fair WR, Cordon-Cardo C, Zhang ZF, Dalbagni G, Lacombe L, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, 10.1200/jco.1996.14.10.2646

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer., HERO Study Investigators, Tombal B, Walling J, Kang V, Fan X, Selby B, van Veenhuyzen DF, Bossi A, Akaza H, Tutrone R, Saltzstein DR, George DJ, Cookson MS, Saad F, Shore ND, The New England journal of medicine, 2020, 10.1056/nejmoa2004325

The Immune Landscape of Cancer., Shmulevich I, Paull EO, Culhane AC, Ziv E, Eddy JA, Plaisier CL, Gao GF, Porta-Pardo E, Ou Yang TH, Bortone DS, Wolf D, Brown SD, Gibbs DL, Thorsson V, Immunity, 2018, 10.1016/j.immuni.2018.03.023

Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy., Fradet V, Têtu B, Fradet Y, Lacombe L, Caron A, Léger C, Nguilé-Makao M, Hovington H, Desmeules P, Diagnostic pathology, 2015, 10.1186/s13000-015-0294-0

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial., C-100-12 RCC Study Group, Figlin R, Flanigan R, Isakov L, Teofilovici F, Hoos A, Zielinski H, Mulders P, Gorelov S, Gorelov AI, Lacombe L, Bukowski R, Srivastava P, Wood C, Lancet (London, England), 2008, 10.1016/s0140-6736(08)60697-2

Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy., Fradet Y, Mian M, Puppo P, Naselli A, Lacombe L, Lodde M, World journal of urology, 2012, 10.1007/s00345-012-0827-z

Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence., Cordon-Cardo C, Fradet Y, Meyer F, Rabbani F, Moore L, Lacombe L, Osman I, LaRue H, Orlow I, The American journal of pathology, 1999, 10.1016/s0002-9440(10)65105-x

Genomic hallmarks of localized, non-indolent prostate cancer., Boutros PC, Prokopec SD, Xie M, Fox NS, Masella AP, Lin X, Yousif F, Shiah YJ, Huang V, Livingstone J, Heisler LE, Yamaguchi TN, Sabelnykova VY, Fraser M, Nature, 2017, 10.1038/nature20788

2011 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2011

A phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation, Vincent Fradet, Yves Fradet, Pierre Julien, Josée Savard, Thierry Duchesne, Martine Perigny, Dominique Trudel, Étienne Racine, Michele Lodde, Paul Toren, Thierry Dujardin, Yves Caumartin, Rabi Tiguert, Louis Lacombe, Nikunj Gevariya, Lisanne Beaudoin, Jean-François Pelletier, Hélène Hovington, Hui Wen Xu, Afshin Jamshidi, Marie-Hélène Guertin, Karine Robitaille, Communications Medicine, 2024, 10.1038/s43856-024-00456-4

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma., Linehan WM, Godwin AK, Gibbs RA, Choueiri TK, Bottaro DP, Beroukhim R, Akbani R, Gibb EA, Bowlby R, Reznik E, Lang M, Smith CC, Fan H, De Cubas AA, Ricketts CJ, Cell reports, 2018, 10.1016/j.celrep.2018.03.075

Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer., Fradet Y, Têtu B, Lacombe L, Bédard C, Bairati I, Meyer F, Urology, 2001, 10.1016/s0090-4295(01)01245-6

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma., Zoledronic Acid Prostate Cancer Study Group, Chen B, Goas JA, Vinholes JJ, Chin JL, Lacombe L, Venner P, Tchekmedyian S, Murray R, Gleason DM, Saad F, Journal of the National Cancer Institute, 2002, 10.1093/jnci/94.19.1458

Comprehensive Characterization of Cancer Driver Genes and Mutations., Ding L, Wang Z, Cao S, Jeong KJ, Ng PK, Reardon B, Kim J, Wendl MC, Colaprico A, Weerasinghe A, Bertrand D, Sengupta S, Porta-Pardo E, Tokheim C, Bailey MH, Cell, 2018, 10.1016/j.cell.2018.02.060

Age ≥ 80 years is independently associated with survival outcomes after radical cystectomy: results from the Canadian Bladder Cancer Network Database., Estey EP, Lattouf JB, Drachenberg DE, Cagiannos I, Bell D, Rendon RA, Lacombe L, Fradet Y, Izawa JI, Chin JL, Aprikian AG, Kassouf W, Fairey AS, Urologic oncology, 2011, 10.1016/j.urolonc.2011.07.014

Conditional survival after radical nephroureterectomy for upper tract carcinoma., Kassouf W, Kapoor A, Scherr DS, Seitz C, Remzi M, Montorsi F, Karakiewicz PI, Matsumoto K, Rouprêt M, Margulis V, Novara G, Lotan Y, Xylinas E, Ploussard G, European urology, 2014, 10.1016/j.eururo.2014.08.003

FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy., Pouliot F, Bouchard F, Rimac G, Tiguert R, Dujardin T, Lacombe L, Lemay C, Fradet Y, Caron A, Fradet V, Blouin AC, Beauregard JM, Cancer imaging : the official publication of the International Cancer Imaging Society, 2015, 10.1186/s40644-015-0038-0

Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach., International Bladder Cancer Nomogram Consortium, Bochner BH, Dalbagni G, Milowsky MI, Scardino PT, Gonen M, Kattan MW, Cronin AM, Vickers AJ, Cancer, 2009, 10.1002/cncr.24615

Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer., Aprikian A, Têtu B, Lacombe L, Carmel M, Saad F, Thibodeau V, Aprikian S, O'Flaherty A, McKercher G, Scarlata E, Chevalier S, Brimo F, Wissing M, BJU international, 2018, 10.1111/bju.14512

Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative., Kapoor A, Jewett MAS, Liu Z, Saarela O, Pautler S, Drachenberg D, Kawakami J, Black PC, Lacombe L, Breau RH, Moore RB, Rendon R, Finelli A, Tanguay S, Bansal RK, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4264

Effect of dutasteride on the risk of prostate cancer., REDUCE Study Group, Wilson TH, Somerville MC, Tindall DJ, Teloken C, Tammela TL, Pettaway CA, Montorsi F, Marberger M, Gomella LG, Brawley OW, Bostwick DG, Andriole GL, The New England journal of medicine, 2010, 10.1056/nejmoa0908127

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer., PROSPER Investigators, Noerby B, Cubero DIG, Kolinsky MP, Madziarska K, Efstathiou E, Ferreira U, Penson DF, De Giorgi U, Shore ND, Saad F, Fizazi K, Sternberg CN, The New England journal of medicine, 2020, 10.1056/nejmoa2003892

Factors Affecting Interindividual Variability of Hepatic UGT2B17 Protein Expression Examined Using a Novel Specific Monoclonal Antibody., Lévesque E, Fallon JK, Têtu B, Périgny M, Caron P, Simonyan D, Lacombe L, Brisson H, Hovington H, Villeneuve L, Rouleau M, Desjardins S, Labriet A, Émond JP, Drug metabolism and disposition: the biological fate of chemicals, 2019, 10.1124/dmd.119.086330

Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy., Pouliot F, Fradet Y, Fradet V, Lacombe L, Nguile Makao M, Bergeron M, Beauregard JM, Morin F, European urology focus, 2017, 10.1016/j.euf.2017.02.007

Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images., Thorsson V, Cancer Genome Atlas Research Network, Van Arnam J, Batiste R, Zhao T, Shroyer KR, Samaras D, Nguyen V, Singh P, Kurc T, Hou L, Gupta R, Saltz J, Cell reports, 2018, 10.1016/j.celrep.2018.03.086

Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium., Tu D, Parulekar WR, Gleave M, Trpkov K, Lacombe L, Siemens DR, Jansz K, Farley A, Hersey K, Chin J, Tanguay S, Donnelly B, Kapusta L, Fleshner NE, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, 10.1200/jco.2010.32.0994

Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series., Lodde M, Toren P, Fradet Y, Lacombe L, Lemire F, Pycha A, Comploj E, Fradet V, Fritsche HM, Tandogdu Z, Mayr R, Ladurner C, Haider M, Urologic oncology, 2019, 10.1016/j.urolonc.2019.01.017

Low level of the X-linked ribosomal protein S4 in human urothelial carcinomas is associated with a poor prognosis., Lebel M, Fradet Y, Lacombe L, Têtu B, Larue H, Lacombe C, Brisson H, Hovington H, Paquet ÉR, Biomarkers in medicine, 2015, 10.2217/bmm.14.115

Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas., Van Waes C, Cherniack AD, Shih J, Coarfa C, Creighton CJ, Byers LA, Akbani R, Wang C, Walter V, Taylor AM, Fan H, Brennan K, Liu Y, Bowlby R, Yau C, Campbell JD, Cell reports, 2018, 10.1016/j.celrep.2018.03.063

Canadian Urological Association 62nd Annual Meeting, Quebec City, QC, June 24-27, 2006., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2007

2018 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018

Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study., Fradet V, Lacombe L, Fradet Y, Nguilé-Makao M, Ben-Zvi T, Léger C, Allaire J, Nutrition and cancer, 2017, 10.1080/01635581.2017.1367941

2009 CUA Abstracts, Kassouf W, Hassouna M, Farrokhyar F, Pinthus J, Goessl C, Leder B, Kupic A, Ke C, Szwedowski M, Heracek J, Tammela T, Feldman R, Egerdie B, Smith M, Saad F, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009

The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation., Saad F, Klotz L, Karakiewicz P, Gleave M, Fleshner NE, Fazli L, Drachenberg D, Chevalier S, Bristow RG, Brimo F, Bergeron A, Aprikian A, Ouellet V, BMC urology, 2018, 10.1186/s12894-018-0392-x

Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation., Wiznerowicz M, Czerwińska P, Colaprico A, Gevaert O, Omberg L, Huelsken J, Kamińska B, Weinstein JN, Poisson L, Burzykowski T, Gentles AJ, Sokolov A, Malta TM, Cell, 2018, 10.1016/j.cell.2018.03.034

Northeastern Section of the American Urological Association 64(th) Annual Meeting, Niagara Falls, Ontario Scientific Program., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012

A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores., Karakiewicz PI, Gleave ME, Fleshner NE, Lacombe L, Aprikian AG, Budäus L, Graefen M, Ouellet V, Tam C, Grosset AA, Zaffuto E, Latour M, Trudel D, Leyh-Bannurah SR, Pathology oncology research : POR, 2018, 10.1007/s12253-018-0408-6

The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience., Rendon RA, Matsumoto E, Saad F, Lattouf JB, So A, Chin J, Tanguay S, Black P, Izawa J, Fairey A, Jacobsen N, Kapoor A, Lacombe L, Bell DG, Kassouf W, Mason RJ, Urology, 2012, 10.1016/j.urology.2011.11.058

PROGRAMME SCIENTIFIQUE : Samedi, le 15 novembre 2008, Session scientifique VIII, Aprikian A, Chevallier S, Bladou F, Rocchi P, Andrieu C, Karsenty G, Cury J, Aprikian A, Steinberg J, Tanguay S, Kassouf W, Jeyaganth S, Amin M, Fahmy N, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2008

The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy., Lévesque É, Guillemette C, Douville P, Fradet V, Fradet Y, Lacombe L, Bellemare J, Audet-Walsh É, European urology, 2011, 10.1016/j.eururo.2011.12.021

Résumés AUQ 2021., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7674

Surgical management of stage T1 renal tumours at Canadian academic centres., Breau RH, Lattouf JB, Black PC, Drachenberg DE, Kawakami J, Pautler SE, Lacombe L, Moore RB, Rendon RA, Kapoor A, Wood L, Jewett MA, Tanguay S, Lavallée LT, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015, 10.5489/cuaj.2598

Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy., Aprikian AG, Lacombe L, Rendon RA, Izawa J, So A, Moore R, Bochner BH, Zlotta A, Kamat AM, Kassouf W, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2010, 10.5489/cuaj.10051

Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival., Fradet Y, Bergeron A, Lacombe L, Hovington H, Simonyan D, Brisson H, Toren P, World journal of urology, 2020, 10.1007/s00345-020-03358-x

Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma., Fradet Y, Saourine A, Morin F, Friede J, Lacombe L, Lodde M, BJU international, 2010, 10.1111/j.1464-410x.2010.09212.x

Early detection of prostate cancer local recurrence by urinary prostate-specific antigen., Tremblay RR, Fradet Y, Lacombe L, Inman BA, Bolduc S, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009, 10.5489/cuaj.1074

2012 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012

Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience., Kassouf W, Drachenberg D, Saad F, Bell D, Lattouf JB, Lacombe L, Cagiannos I, Fairey A, Estey E, Rendon R, Izawa J, Chin JL, Fradet Y, Aprikian AG, Yafi FA, BJU international, 2012, 10.1111/j.1464-410x.2012.11133.x

Northeastern Section of the American Urological Association 63(rd) Annual Meeting, New Orleans, Louisiana October 26 - 30, 2011 Scientific Program., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2011

Female urethral carcinoma: an analysis of treatment outcome and a plea for a standardized management strategy., Herr HW, Lacombe L, Zhang ZF, Dalbagni G, British journal of urology, 1998, 10.1046/j.1464-410x.1998.00878.x

Erratum to "The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System" [Urol Oncol 34(11) (2016) 486.e1-486.e7]., Rendon RA, Black P, Morash C, Moore R, Kawakami J, Lacombe L, Finelli A, Jewett M, Tanguay S, Saarela O, Liu Z, Kapoor A, Mason R, Urologic oncology, 2017, 10.1016/j.urolonc.2017.01.018

Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression, Eric Lévesque, Chantal Guillemette, Simone Chevalier, Michel Carmel, Fred Saad, Armen Aprikian, David Simonyan, Véronique Turcotte, Patrick Caron, Louis Lacombe, Jean-Philippe Emond, British Journal of Cancer, 2021, 10.1038/s41416-021-01376-z

A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples., Liang H, Cancer Genome Atlas Research Network, Weinstein JN, Zhou Z, Peng X, Li C, Chen H, Cell, 2018, 10.1016/j.cell.2018.03.027

A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study., Canadian Urology Research Consortium, Chin JL, Zhang L, Kebabdjian M, McNeill IY, Klotz LH, European urology, 2012, 10.1016/j.eururo.2012.09.007

Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy., Fradet Y, Moore L, Veilleux C, Meyer F, Maillette A, Lacombe L, International journal of cancer, 2001, 10.1002/1097-0215(20010520)95:3<135::aid-ijc1023>3.0.co;2-3

Regional differences in practice patterns and outcomes in patients treated with radical cystectomy in a universal healthcare system., Kassouf W, Drachenberg D, Saad F, Bell D, Lattouf JB, Lacombe L, Cagiannos I, Fairey A, Estey E, Rendon R, Izawa J, Chin JL, Fradet Y, Aprikian AG, Bachir BG, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2013, 10.5489/cuaj.201

The Molecular Taxonomy of Primary Prostate Cancer., Cancer Genome Atlas Research Network, Cell, 2015, 10.1016/j.cell.2015.10.025

Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context., Sumazin P, Sood AK, Cancer Genome Atlas Research Network, Chatterjee SS, Pan Y, Patil SL, Zorman B, Singh VP, Chen TW, Patel E, Somvanshi S, Chiu HS, Cell reports, 2018, 10.1016/j.celrep.2018.03.064

Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors., Fradet Y, Dujardin T, Tiguert R, Pouliot F, Lacombe L, Ben-Zvi T, Bergeron A, Caron A, Léger C, Lévesque J, Lodde M, Nguile-Makao M, Toren P, Fradet V, BJU international, 2017, 10.1111/bju.14041

Radical cystectomyfor clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcome, , 2012

Podium Session 1: Prostate Cancer June 26, 2016 1050–1150, Gleave M, Ouellet V, Timilshina N, Shore N, Forer D, Wang F, Hasabou N, van Os S, Baron B, Villers A, Chowdhury S, Heidenreich A, Klotz H, Siemens D, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2016

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics., Hu H, Shriver CD, Wolf DM, Omberg L, Lee AV, Levine DA, Benz CC, Kovatich AJ, Cherniack AD, Lazar AJ, Poisson LM, Hoadley KA, Lichtenberg T, Liu J, Cell, 2018, 10.1016/j.cell.2018.02.052

Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence., Fradet Y, Meyer F, Têtu B, Lacombe L, Larue H, Allard P, Moore L, Pfister C, Clinical cancer research : an official journal of the American Association for Cancer Research, 1999

Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy., Fradet Y, Lacombe L, Têtu B, Bergeron A, Harel F, Decobert M, Hovington H, LaRue H, Ayari C, European urology, 2009, 10.1016/j.eururo.2009.01.040

Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality., Lacombe L, Fradet Y, Tran VT, Inman BA, Cancer, 2009, 10.1002/cncr.24339

Systematic Analysis of Splice-Site-Creating Mutations in Cancer., Ding L, Liang WW, Huang M, Varghese R, Wang F, Chai S, Climente-González H, Zhao Y, Reynolds SM, Vo NS, Wendl MC, Gao Q, Cao S, Jayasinghe RG, Cell reports, 2018, 10.1016/j.celrep.2018.03.052

Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer., Liang H, Han L, Zhang H, Chen Z, Li J, Chen H, Ge Z, Peng X, Bhavana VH, Moreno D, Tsang YH, Jeong KJ, Ng PK, Mojumdar K, Dill MT, Xu X, Maglic D, Wang Y, Cell reports, 2018, 10.1016/j.celrep.2018.10.001

Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network., Canadian Prostate Cancer Biomarker Network, Gleave M, Fleshner N, Fazli L, Chevalier S, Bergeron A, Aprikian A, Latour M, Delvoye N, Barrès V, Fragoso G, Caron C, Ouellet V, Grosset AA, PLoS medicine, 2019, 10.1371/journal.pmed.1002847

Abstraits AUQ 2016 Programme Scientifique - Session 1, Gebhart J, Fragoso G, Barrès V, Péant B, Ouellet V, Clairefond* S, Campeau L, Corcos J, Biardeau X, Shamout* S, Bolduc S, Moore K, Nadeau G, Ramsay* S, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2016

ABSTRAITS AUQ 2017., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4968

Achieving the "trifecta" with open versus minimally invasive partial nephrectomy., Black PC, Tanguay S, Liu Z, Jewett M, Fairey A, Lacombe L, Lavallee L, Breau RH, Moore RB, Kapoor A, Finelli A, Rendon RA, Pouliot F, Saarela O, Ghavimi S, World journal of urology, 2020, 10.1007/s00345-020-03349-y

Banking of fresh-frozen prostate tissue using the alternate mirror image protocol: methods, validation, and impact on the pathological prognostic parameters in radical prostatectomy., Aprikian A, Scarlata E, Têtu B, Lacombe L, Saad F, Chevalier S, Sircar K, Brimo F, Cell and tissue banking, 2011, 10.1007/s10561-011-9284-y

Discordance between testosterone measurement methods in castrated prostate cancer patients., Pouliot F, Guérette D, Saad F, Klotz L, Lacombe L, Guillemette C, Toren P, Fradet Y, Dubois G, Thériault B, Déry M, Lemire F, Rouleau M, Endocrine connections, 2019, 10.1530/ec-18-0476

Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types., Yu L, Buonamici S, Cancer Genome Atlas Research Network, Smith PG, Zhu P, Teng T, Palacino J, Agrawal AA, Peng S, Seiler M, Cell reports, 2018, 10.1016/j.celrep.2018.01.088

Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer., Fradet Y, Lacombe L, Lodde M, Urology, 2010, 10.1016/j.urology.2009.12.057

PROGRAMME SCIENTIFIQUE : Vendredi, le 14 novembre 2008, Session scientifique V, Fradet Y, Asker A, Letendre J, Jeldres C, Baillargeon-Gagné S, Fradet Y, Lacombe L, Larue H, Harel F, Hovington H, Lessard A, Blackburn F, Moore K, Aziz A, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2008

Driver Fusions and Their Implications in the Development and Treatment of Human Cancers., Ding L, Sun SQ, Yu L, Yao L, Wyczalkowski MA, Reynolds SM, Liao WW, Cao S, Jayasinghe RG, Mutharasu G, Foltz SM, Liang WW, Gao Q, Cell reports, 2018, 10.1016/j.celrep.2018.03.050

Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version., Kassouf W, Rendon RA, McPherson V, Lacombe L, Izawa JI, Hanna N, French C, Fairey A, Brimo F, Breau RH, Aprikian AG, Siemens DR, Kulkarni GS, Kool R, Bhindi B, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7487

2010 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2010

Can biological markers predict recurrence and progression of superficial bladder cancer?, Lacombe L, Fradet Y, Current opinion in urology, 2000, 10.1097/00042307-200009000-00013

Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL., Tremblay RR, Fradet Y, Grégoire M, Naud A, Lacombe L, Bolduc S, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2007, 10.5489/cuaj.444

lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer., Yang D, Xie W, Cancer Genome Atlas Research Network, Li S, Jia L, Wang Y, Wu Z, Guo W, Zhang M, Yang B, Wang Z, Cancer cell, 2018, 10.1016/j.ccell.2018.03.006

PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression., Kwon ED, Lacombe L, Fradet Y, Frank I, Bergstralh EJ, Dong H, Frigola X, Sebo TJ, Inman BA, Cancer, 2007, 10.1002/cncr.22588

Northeastern Section of the AUA 72nd Annual Meeting Abstracts, Skog J, Bjazevic J, Burton J, Razvi H, Al K, Spierling A, Li X, Bjazevic J, Kim H, Abston K, Doersch K, Samarakoon R, Higgins P, Lian F, Tang J, Donnelly L, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020

Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics., Cancer Genome Atlas Research Network, Jayasinghe R, Cortés-Ciriano I, Tokheim C, Huang KL, Weerasinghe A, Gibbs DL, Bertrand D, Colaprico A, Thorsson V, Porta-Pardo E, Bailey MH, Ding L, Cell, 2018, 10.1016/j.cell.2018.03.033

Male urethral carcinoma: analysis of treatment outcome., Herr HW, Lacombe L, Zhang ZF, Dalbagni G, Urology, 1999, 10.1016/s0090-4295(98)00659-1

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer., Laird PW, Wiznerowicz M, Wong CK, Bowlby R, Akbani R, Thorsson V, Cherniack AD, Taylor AM, Shen R, Drill E, Lazar AJ, Wolf DM, Hinoue T, Yau C, Hoadley KA, Cell, 2018, 10.1016/j.cell.2018.03.022

Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation., Guillemette C, Lévesque É, Pouliot F, Lacombe L, Villeneuve L, Caron P, Turcotte V, Vaillancourt J, Drug metabolism and disposition: the biological fate of chemicals, 2019, 10.1124/dmd.119.088229

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer., PROfound Trial Investigators, Roubaud G, Twardowski P, Thiery-Vuillemin A, Olmos D, Agarwal N, Sartor O, Chi KN, Sandhu S, Shore N, Saad F, Fizazi K, Mateo J, Hussain M, The New England journal of medicine, 2020, 10.1056/nejmoa2022485

Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer, Chantal Guillemette, Eric Lévesque, Simone Chevalier, Michel Carmel, Fred Saad, Armen Aprikian, Louis Lacombe, Patrick Caron, Véronique Turcotte, Flora Nguyen Van Long, Michèle Rouleau, British Journal of Cancer, 2023, 10.1038/s41416-022-02040-w

The Immune Landscape of Cancer., Shmulevich I, Paull EO, Culhane AC, Ziv E, Eddy JA, Plaisier CL, Gao GF, Porta-Pardo E, Ou Yang TH, Bortone DS, Wolf D, Brown SD, Gibbs DL, Thorsson V, Immunity, 2019, 10.1016/j.immuni.2019.08.004

Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer., Bao BY, Juang SH, Lee HZ, Chang TY, Fradet Y, Lacombe L, Laverdière I, Chen LC, Chung IC, Lin VC, Huang CY, Yu CC, Guillemette C, Lévesque E, Huang SP, International journal of cancer, 2014, 10.1002/ijc.28904

CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy., Wu L, Lacombe L, Fradet Y, Bollag G, West BL, Deng G, Xu J, Sung JL, Magyar C, Pouliot F, Jiang Z, Moughon D, Priceman SJ, Liu C, Schokrpur S, Escamilla J, Cancer research, 2015, 10.1158/0008-5472.can-14-0992

2014 CUA Abstracts, Davies T, Morash C, Moore R, Black P, Kapoor A, Liu Z, Tanguay S, Mason R, Finelli A, Evans A, Kachura J, Komisarenko M, Jewett M, Bhatt J, Richard P, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2014

Abstraits AUQ 2018, Saad F, Rouleau M, Lemire F, Kassouf W, Mansure J, Seuntjens J, Piccirilo C, Shinde S, Ayoub M, Rompré-Brodeur A, Bolduc S, Moore K, Ramsay S, Naud E, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018

Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction., Guillemette C, Fradet Y, Harvey M, Nguile-Makao M, Caron A, Hovington H, Bergeron A, Larue H, Pouliot F, Lévesque É, Fradet V, Lacombe L, Cancer prevention research (Philadelphia, Pa.), 2015, 10.1158/1940-6207.capr-15-0069

Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2., Lacombe L, Fradet Y, Larue H, Latulippe E, Hovington H, Moore K, Lessard A, Aziz A, BJU international, 2010, 10.1111/j.1464-410x.2010.09909.x

Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas., Laird PW, Akbani R, Chatila W, Kim J, Islam M, Bowlby R, Farshidfar F, Seoane JA, Sanchez-Vega F, Cherniack AD, Schneider BG, Hinoue T, Sethi NS, Liu Y, Cancer cell, 2018, 10.1016/j.ccell.2018.03.010

2009 CUA Abstracts, Haider M, Carrier S, Casey R, Bénard F, Hodges S, Atala A, McLorie G, Bolduc S, Lamontagne P, Hamel M, Lebel S, Cloutier J, Boucher A, Ruwali A, Al Mandil M, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009

Leukocytic Infiltration of Intraductal Carcinoma of the Prostate: An Exploratory Study, Dominique Trudel, Yves Fradet, Alain Bergeron, Louis Lacombe, Bernard Têtu, Hélène Hovington, Hélène LaRue, Mirela Birlea, Oscar Eduardo Molina, Mame-Kany Diop, Cancers, 2023, 10.3390/cancers15082217

Comprehensive Characterization of Cancer Driver Genes and Mutations., Ding L, Jeong KJ, Kwok-Shing Ng P, Reardon B, Kim J, Wendl MC, Colaprico A, Weerasinghe A, Bertrand D, Sengupta S, Porta-Pardo E, Tokheim C, Bailey MH, Cell, 2018, 10.1016/j.cell.2018.07.034

Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?, Toren P, Lodde M, Fradet Y, Fradet V, Lacombe L, McMartin C, Clinical genitourinary cancer, 2019, 10.1016/j.clgc.2019.07.016

Genome-wide germline correlates of the epigenetic landscape of prostate cancer., Boutros PC, Livingstone J, Heisler LE, Fraser M, Huang V, O'Connor E, Bell C, Yao CQ, Ramanand SG, Shetty A, Yuan J, Ahmed M, Gusev A, Shiah YJ, Houlahan KE, Nature medicine, 2019, 10.1038/s41591-019-0579-z

Congrés Annuel : Programme général Association des Urologues du Québec, Delouya G, Bernard G, Rousseau A, Taillon G, Morissette A, Orabi H, Bouchard *, Fred S, Thomas G, Anne-Marie M, Jennifer K, Lateef A, Melina A, Benjamin *, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2014

Message from our President, Romao R, Filler G, Bjazevic J, Wang Z, Berto F, Gilling P, Kaplan S, Roehrborn R, Desai M, Paterson R, So A, Goldenberg S, Elterman D, Bhojani N, Zorn K, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020

The relationship between body-mass index, physical activity, and pathologic and clinical outcomes after radical prostatectomy for prostate cancer., Aprikian A, Latour M, Brimo F, Lacombe L, Carmel M, Saad F, Scarlata E, O'Flaherty A, Aprikian S, Laprise C, McKercher G, Chevalier S, Wissing M, World journal of urology, 2018, 10.1007/s00345-018-2457-6

A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer., Guillemette C, Chevalier S, Carmel M, Saad F, Aprikian A, Fradet Y, Simonyan D, Turcotte V, Lacombe L, Caron P, Lévesque E, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2019, 10.1158/1055-9965.epi-18-1002

Complete Penile Necrosis in a Patient With Heparin-induced Thrombocytopenia: A Case Report., Lacombe L, Deschênes Rompré MP, Blais AS, Urology case reports, 2014, 10.1016/j.eucr.2013.12.003

Genotypic and phenotypic characterization of the histoblood group ABO(H) in primary bladder tumors., Cordón-Cardó C, Szijan I, Zhang ZF, Delgado R, Rabbani F, Pellicer I, Lacombe L, Orlow I, International journal of cancer, 1998, 10.1002/(sici)1097-0215(19980316)75:6<819::aid-ijc1>3.0.co;2-y

Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival., Lacombe L, Fradet Y, Douville P, Meyer F, Audet JF, Harel F, Inman BA, European urology, 2005, 10.1016/j.eururo.2004.12.015

Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration., Jacobsen NE, Drachenberg D, Saad F, Lattouf JB, So A, Black P, Matsumoto E, Kapoor A, Chin J, Izawa J, Bell D, Rendon R, Tanguay S, Estey E, Kassouf W, Fairey AS, BJU international, 2012, 10.1111/j.1464-410x.2012.11474.x

Renal cell carcinoma with thrombus extending to the hepatic veins or right atrium: operative strategies based on 41 consecutive patients., Dagenais F, Fradet V, Pouliot F, Lacombe L, Gagné-Loranger M, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2016, 10.1093/ejcts/ezw023

Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure., Fradet Y, Têtu B, Lacombe L, Bairati I, Moore L, Meyer F, The Journal of urology, 1999, 10.1016/s0022-5347(05)68092-5

Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience., Izawa JI, Lattouf JB, Drachenberg D, Cagiannos I, Bell D, Rendon R, Lacombe L, Estey E, Fairey AS, Aprikian AG, Fradet Y, Chin JL, Kassouf W, Chalasani V, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2011, 10.5489/cuaj.10040

Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types., Liang H, Cancer Genome Atlas Research Network, Hu H, Shriver CD, Liu J, Zhang H, Li J, Yao F, Sun Y, Chen H, Chen Z, Peng X, Wang Y, Leighton JS, Ge Z, Cell reports, 2018, 10.1016/j.celrep.2018.03.047

Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome., Kassouf W, Saad F, Fradet Y, Bell D, Lattouf JB, So A, Chin J, Lacombe L, Black P, Kapoor A, Izawa J, Fairey A, Jacobsen N, Rendon R, Tanguay S, Yafi FA, Urologic oncology, 2013, 10.1016/j.urolonc.2012.11.014

Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma., Aprikian AG, Tanguay S, Wood CG, Chetner M, Chin J, Goldenberg L, Jewett M, Lacombe L, Morash C, Siemens R, Kassouf W, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009, 10.5489/cuaj.1028

Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway., Guillemette C, Lacombe L, Fradet Y, Rouleau M, Caron P, Audet-Walsh E, Laverdière I, Lévesque E, Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, 10.1158/1078-0432.ccr-13-2567

Psychosocial adjustment to a prostate cancer diagnosis in a cohort of radical prostatectomy patients in Quebec, Canada., Aprikian A, Hamel M, Lacombe L, Carmel M, Saad F, Aprikian S, McKercher G, O'Flaherty A, Chevalier S, Wissing MD, Psycho-oncology, 2019, 10.1002/pon.5031

Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer., Toren P, Lacombe L, Fradet Y, Julien AS, Cyr SJ, Pelletier J, Urologic oncology, 2018, 10.1016/j.urolonc.2018.05.004

Genomic and Functional Approaches to Understanding Cancer Aneuploidy., Meyerson M, Cancer Genome Atlas Research Network, Lazar AJ, Liu J, Hu H, Wang C, Schumacher SE, Berger AC, Zhang X, Gao GF, Ha G, Shih J, Taylor AM, Cancer cell, 2018, 10.1016/j.ccell.2018.03.007

Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA), Vincent Fradet, Caroline Diorio, Josée Savard, Pierre Julien, Thierry Duchesne, Yves Caumartin, Thierry Dujardin, Rabi Tiguert, Michele Lodde, Paul Toren, Louis Lacombe, Yves Fradet, Roxane Tourigny, Jean-François Pelletier, Karine Robitaille, Hanane Moussa, Nutrients, 2023, 10.3390/nu15061369

Deletion of the p16 and p15 genes in human bladder tumors., Cordon-Cardo C, Beach D, Zhang ZF, Reuter VE, Dalbagni G, Pellicer I, Serrano M, Hannon GJ, Lacombe L, Orlow I, Journal of the National Cancer Institute, 1995, 10.1093/jnci/87.20.1524

SRD5A polymorphisms and biochemical failure after radical prostatectomy., Lévesque E, Guillemette C, Girard H, Douville P, Bao BY, Huang SP, Fradet V, Fradet Y, Lacombe L, Nadeau G, Bellemare J, Audet-Walsh E, European urology, 2011, 10.1016/j.eururo.2011.06.020

[Clinical value of the study of proliferation and cell activation antigens with flow cytometry in bladder cancer]., Fradet Y, Lafleur L, Gauthier J, Lacombe L, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 1996

A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine., Pouliot F, Lacombe L, Fradet Y, Dujardin T, Deschênes-Rompré MP, Cloutier J, Caumartin Y, Bureau M, Bolduc S, Blouin AC, Blais AS, Paquet S, Turcotte B, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020, 10.5489/cuaj.6862

Double inferior vena cava systems during retroperitoneal surgery: Description of a systematic approach to a rare and challenging anatomic variant., Dagenais F, Lacombe L, Chaud GJ, Journal of vascular surgery cases and innovative techniques, 2021, 10.1016/j.jvscit.2021.12.003

Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas., Wang C, Donehower LA, Feng B, Akbani R, Liu Y, Greene CS, Way GP, Shen H, Fan H, Cherniack AD, Gao GF, Chambwe N, Zimmermann MT, Wang L, Knijnenburg TA, Cell reports, 2018, 10.1016/j.celrep.2018.03.076

Denosumab in men receiving androgen-deprivation therapy for prostate cancer., Denosumab HALT Prostate Cancer Study Group, Goessl C, Leder BZ, Kupic A, Ke C, Szwedowski M, Heracek J, Saad F, Tammela TL, Feldman R, Hernández Toriz N, Egerdie B, Smith MR, The New England journal of medicine, 2009, 10.1056/nejmoa0809003

Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy., Fradet Y, Lacombe L, Larue H, Laverdiere J, Latulippe E, Hovington H, Decobert M, Tiguert R, Rigaud J, The Prostate, 2004, 10.1002/pros.10329

Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer., Black PC, Liu Z, Saarela O, Jewett MMA, Pautler SE, Drachenberg DE, Kawakami J, Lacombe L, Breau RH, Moore RB, Kapoor A, Finelli A, Rendon RA, Forbes CM, Urologic oncology, 2016, 10.1016/j.urolonc.2016.05.034

The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System., Rendon RA, Black P, Morash C, Moore R, Kawakami J, Lacombe L, Finelli A, Jewett M, Tanguay S, Saarela O, Liu Z, Kapoor A, Mason R, Urologic oncology, 2016, 10.1016/j.urolonc.2016.05.025

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer., SPARTAN Investigators, Espina BM, Trudel GC, Lopez-Gitlitz A, Uemura H, Lee JY, Mainwaring PN, Olmos D, Graff JN, Hadaschik BA, Oudard S, Chowdhury S, Saad F, Smith MR, The New England journal of medicine, 2018, 10.1056/nejmoa1715546

Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma., Black PC, Fairey AS, Fradet Y, Lacombe L, Saad F, Lattouf JB, Shayegen B, Kapoor A, Chin J, Izawa J, Bell D, Rendon RA, Kassouf W, Hamidizadeh R, Locke JA, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018, 10.5489/cuaj.5377

Insomnia in men treated with radical prostatectomy for prostate cancer., Fradet Y, Lacombe L, Ivers H, Hervouet S, Simard S, Savard J, Psycho-oncology, 2005, 10.1002/pon.830

Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer., Cordon-Cardo C, Zhang ZF, Dalbagni G, Fair WR, Reuter VE, Orlow I, Lacombe L, International journal of cancer, 1996, 10.1002/(sici)1097-0215(19960422)69:2<110::aid-ijc7>3.0.co;2-3

Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: how much is enough?, Lacombe L, Fradet Y, Harel F, Meyer F, LaRue H, Decobert M, Cancer, 2008, 10.1002/cncr.23627

Outcomes of pT0N0 at radical cystectomy: The Canadian Bladder Cancer Network experience., Drachenberg D, Kassouf W, Bell D, Lattouf JB, Lacombe L, Cagiannos I, Rendon R, Fairey A, Estey E, Izawa J, Fradet Y, Chin J, Aprikian A, Sandhu GS, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012, 10.5489/cuaj.11276

The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression., Lévesque E, Guillemette C, Lacombe L, Fradet Y, Têtu B, Simonyan D, Villeneuve L, Brisson H, Caron P, Garcia L, Hovington H, Belledant A, European urology, 2015, 10.1016/j.eururo.2015.06.054

Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes., Drachenberg DE, Kawakami J, Breau RH, Lacombe L, Black PC, Moore R, Rendon R, Tanguay S, Finelli A, Kapoor A, Liu Z, Saarela O, Patel P, Nayak JG, Urology, 2016, 10.1016/j.urology.2016.03.029

Does the potassium stimulation test predict cystometric, cystoscopic outcome in interstitial cystitis?, Fradet Y, Lacombe L, Naud A, Liandier F, Grégoire M, The Journal of urology, 2002, 10.1016/s0022-5347(05)64678-2

Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression., Latres E, Lianes P, Ponce-Castaneda V, Lacombe L, Orlow I, Eeles R, Frye C, Liu Q, Weaver-Feldhaus J, Gruis NA, The American journal of pathology, 1995

Comorbidity status does not independently predict survival outcomes after radical nephroureterectomy for upper tract urothelial carcinoma., Kassouf W, Saad F, Lattouf JB, So A, Black P, Matsumoto E, Kapoor A, Chin J, Izawa J, Bell D, Rendon R, Tanguay S, Estey E, Jacobsen NE, Fairey AS, European urology, 2013, 10.1016/j.eururo.2013.06.014

The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence., Kassouf W, Bell D, Lattouf JB, So A, Chin J, Tanguay S, Black P, Izawa J, Fairey A, Jacobsen NE, Rendon R, Lacombe L, Shayegan B, Allard CB, Dason S, Kapoor A, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2014, 10.5489/cuaj.1985

Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma., Izawa JI, Saad F, Fradet Y, Bell D, Lattouf JB, So A, Tanguay S, Lacombe L, Black P, Kapoor A, Fairey A, Jacobsen N, Rendon R, Chin J, Kassouf W, Williams AK, Urologic oncology, 2013, 10.1016/j.urolonc.2011.12.004

Oncogenic Signaling Pathways in The Cancer Genome Atlas., Schultz N, Gao Q, Daian F, Chakravarty D, Saghafinia S, Kantheti HS, Liu DL, Dimitriadoy S, La KC, Luna A, Chatila WK, Armenia J, Mina M, Sanchez-Vega F, Cell, 2018, 10.1016/j.cell.2018.03.035

Increased survival with enzalutamide in prostate cancer after chemotherapy., AFFIRM Investigators, Fléchon A, Flaig TW, Armstrong AJ, Shore ND, Chi KN, Mulders P, de Wit R, Miller K, Sternberg CN, Taplin ME, Saad F, Fizazi K, Scher HI, The New England journal of medicine, 2012, 10.1056/nejmoa1207506

Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers., Liang H, Zhao Z, Zhang H, Liu L, Birsoy K, Thomas GV, Li J, Ge Z, Du D, Mojumdar K, Tan L, Cheng F, Wang Y, Lorenzi PL, Xu X, Farshidfar F, Chen Z, Peng X, Cell reports, 2018, 10.1016/j.celrep.2018.03.077

p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors., Massague J, Sheinfeld J, Krauter K, Mathew S, Montgomery K, Lacombe L, Polyak K, Latres E, Lee MH, Ponce-Castañeda MV, Cancer research, 1995

Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors., Boutros PC, Lacombe L, Berlin A, Murgic J, Hovington H, Orain M, Yao CQ, Picard V, Zheng J, Meng A, Haider S, Fraser M, Chua MLK, Alkallas R, Lalonde E, European urology, 2016, 10.1016/j.eururo.2016.10.013

Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer., Fradet Y, Lacombe L, Rousseau F, Pfister C, Harel F, Bergeron A, Larue H, Decobert M, The Journal of urology, 2006, 10.1016/s0022-5347(05)00653-1

2017 CUA Abstracts, Braga L, Recker F, Sendorek D, Lalonde E, Kwiatkowski M, Xu J, Ozcelik H, Briollais L, Haider M, Pond G, Kebabdjian M, Fleshner N, Chin J, Loblaw A, Klotz L, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017

2010 NS-AUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2010

Résumés AUQ 2019., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019, 10.5489/cuaj.6229

2009 CUA Abstracts, Luke P, Volinn W, Gittelman M, Marks L, Hill L, Hobart M, Mador D, Schultz T, Araki M, Spaliviero M, Wong C, Kassouf W, Tanguay S, Aprikian A, Yafi F, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009

High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer., Fradet Y, Lacombe L, Hovington H, Harel F, LaRue H, Picard V, Bergeron A, International journal of cancer, 2009, 10.1002/ijc.24503

Widespread and Functional RNA Circularization in Localized Prostate Cancer., He HH, Volik S, Ahmed M, Donmez N, Zhang Y, Yousif F, Wang M, Guo H, Petricca J, Hua JT, Zeng Y, Jeon J, Soares F, Livingstone J, Xu X, Huang V, Chen S, Cell, 2019, 10.1016/j.cell.2019.01.025

Strategies for biochemical and pathologic quality assurance in a large multi-institutional biorepository; The experience of the PROCURE Quebec Prostate Cancer Biobank., Chevalier S, Carmel M, Lacombe L, Saad F, McKercher G, Hamel L, Scarlata E, Doueik A, Têtu B, Latour M, Aprikian A, Brimo F, Biopreservation and biobanking, 2013, 10.1089/bio.2013.0025

Enzalutamide in metastatic prostate cancer before chemotherapy., PREVAIL Investigators, de Bono JS, Davis ID, Chowdhury S, Carles J, Bhattacharya S, Iversen P, Higano CS, Sternberg CN, Loriot Y, Rathkopf DE, Armstrong AJ, Beer TM, The New England journal of medicine, 2014, 10.1056/nejmoa1405095

Psychological functioning associated with prostate cancer: cross-sectional comparison of patients treated with radiotherapy, brachytherapy, or surgery., Lacombe L, Fradet Y, Vigneault E, Laverdière J, Ivers H, Simard S, Savard J, Hervouet S, Journal of pain and symptom management, 2005, 10.1016/j.jpainsymman.2005.05.011

Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines., Cancer Genome Atlas Research Network, Wheeler D, Getz G, Hutter C, Sofia HJ, McLellan M, Chiotti KE, Ma S, Hess J, Stewart C, Kandoth C, Covington KR, Saksena G, Bailey MH, Ellrott K, Cell systems, 2018, 10.1016/j.cels.2018.03.002

Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience., Kassouf W, Drachenberg D, Bell D, Lattouf JB, Lacombe L, Cagiannos I, Rendon R, Fairey A, Estey E, Izawa J, Fradet Y, Chin JL, Aprikian AG, Yafi FA, BJU international, 2010, 10.1111/j.1464-410x.2010.09912.x

Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas., Cancer Genome Atlas Network, Eisenman RN, Cherniack AD, Hurlin PJ, Ayer DE, Liu Y, Ventura A, Zhang X, Zhao W, Shaw R, Richardson AB, Trivedi M, Berger AC, Dhankani V, Schaub FX, Cell systems, 2018, 10.1016/j.cels.2018.03.003

Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort., Rendon RA, Drachenberg D, Lattouf JB, Cagiannos I, Fairey A, Estey E, Izawa J, Chin J, Lacombe L, Fradet Y, Aprikian AG, Bell D, Kassouf W, Power NE, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012, 10.5489/cuaj.11012

Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer., Lévesque E, Guillemette C, Lacombe L, Fradet Y, Caron P, Douville P, Bao BY, Huang SP, Flageole C, Audet-Walsh É, Bellemare J, Nadeau G, The Journal of clinical endocrinology and metabolism, 2011, 10.1210/jc.2011-1049

Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression., Guillemette C, Caron P, Yu CC, Huang CY, Rouleau M, Laverdière I, Fradet Y, Bao BY, Lacombe L, Audet-Walsh É, Huang SP, Lévesque É, Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, 10.1158/1078-0432.ccr-12-2812

2009 AUA-NS Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009

Découvrez nos professeurs et professeures!

Louis Lacombe

Contribution à la recherche

Thématiques de recherche de la Faculté de médecine

Domaines de recherche

Projets de recherche en cours

Financements des 2 dernières années

Publications

Vice-décanat à la recherche et à l'innovation